Czech National Bank Acquires 3,004 Shares of IQVIA Holdings Inc. $IQV

Czech National Bank boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,176 shares of the medical research company’s stock after purchasing an additional 3,004 shares during the period. Czech National Bank’s holdings in IQVIA were worth $8,201,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Everpar Advisors LLC lifted its position in shares of IQVIA by 4.6% during the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock worth $221,000 after buying an additional 62 shares during the period. Private Trust Co. NA lifted its holdings in shares of IQVIA by 12.5% during the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 67 shares during the period. E Fund Management Co. Ltd. boosted its stake in shares of IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 74 shares in the last quarter. Penserra Capital Management LLC grew its holdings in shares of IQVIA by 10.3% in the 2nd quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock worth $151,000 after purchasing an additional 90 shares during the last quarter. Finally, Forte Capital LLC ADV increased its position in shares of IQVIA by 0.3% during the 2nd quarter. Forte Capital LLC ADV now owns 26,809 shares of the medical research company’s stock worth $4,225,000 after purchasing an additional 92 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 0.8%

Shares of IQV opened at $220.75 on Friday. The business’s fifty day moving average price is $219.06 and its two-hundred day moving average price is $192.18. The firm has a market capitalization of $37.59 billion, a price-to-earnings ratio of 30.28, a PEG ratio of 2.50 and a beta of 1.37. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $234.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Morgan Stanley boosted their price target on shares of IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. TD Cowen downgraded IQVIA from a “buy” rating to a “hold” rating and boosted their target price for the stock from $206.00 to $215.00 in a report on Monday, November 3rd. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Truist Financial reiterated a “buy” rating and issued a $265.00 price objective (up previously from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. Finally, Cowen cut IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $243.19.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is owned by company insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.